Gastric Inhibitory Polypeptide (GIP) Antibody
806€ (1 ml)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Gastric Inhibitory Polypeptide (GIP) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx172523
tested applications
WB, IHC, IF/ICC
Description
This product is currently in development. The lead time for this product may be several months. Please contact us at
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Gastric Inhibitory Polypeptide (GIP) |
| Host | Mouse |
| Reactivity | Rat |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Please enquire. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | Glucose-dependent insulinotropic polypeptide,Incretin |
| Background | Antibody anti-GIP |
| Status | RUO |
Descripción
GIP, also called glucose-dependent insulinotropic polypeptide, is a 42-amino acid hormone secreted by K-cells in the duodenum and jejunum in response to nutrient ingestion, particularly glucose, fats, and amino acids GIP acts as a critical incretin hormone that enhances glucose-dependent insulin secretion from pancreatic β-cells by activating cAMP-dependent pathways and protein kinase A signaling GIP also regulates lipid metabolism by stimulating lipoprotein lipase activity in adipose tissue, promoting triglyceride uptake and energy storage GIP further supports bone homeostasis by enhancing osteoblast function, contributing to bone formation and mineralization Dysregulation of GIP levels and signaling is associated with insulin resistance, obesity, and type 2 diabetes where its insulinotropic effects are impaired despite elevated circulating levels GIP-based therapies, including dual GIP/GLP-1 receptor agonists, have shown therapeutic potential in improving glycemic control and promoting weight loss in metabolic disorders
Related Products
Human GIP(Gastric inhibitory polypeptide) ELISA Kit
Ver Producto
Mouse Gip(Gastric inhibitory polypeptide) ELISA Kit
Ver Producto